AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05274035 — intervention group
Intervention type: DRUG
Intervention: Perampanel
Description: For children ≥4 years old, the initial dose is 2 mg per day, the titration interval is ≥2 weeks, the daily dose is increased by 2 mg each time (based on clinical response and tolerability), and the maintenance dose is ≥4 mg per day, up to a maximum dose of 12 mg per day.~For children \<4 years old, the initial dose is 0.04 mg/kg per day, the titration interval is ≥ 2 weeks, the daily dose is increased by 0.04 mg/kg each time (based on clinical response and tolerability), and the maintenance dose is ≥ 0.08 mg/day per day kg, the highest dose is 0.24 mg/kg per day.~According to the actual clinical situation, the initial dose and addition plan are judged by the investigator.
Study NCT05645120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: All participants attended to a two-part nutrition education program. The education intervention program was administered in two sessions, one week apart. Before the intervention, a pre-test was administered to determine the knowledge and beliefs attitudes of participants. After the pre-test each session consisted of a PowerPoint presentation of about 20 minutes. Education topics included components of adequate-balanced nutrition and its relationship with COVID-19, introduction of food groups, the association between COVID-19 and dietary supplements, herbal foods in the prevention/treatment of COVID-19, considerations regarding DS/HF, food-drug interactions, and COVID-19 drugs and food interactions. The presentation was concluded with the nutritional recommendations for COVID-19. The post-tests were shared with the participants at the end of the second session of the education intervention.
Study NCT04744467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
Study NCT05710588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor-motor dual-task training
Description: The intervention compromises balance-related tasks which are selected among the tasks often used in balance rehabilitation and motor secondary tasks might be required hand dexterity like popping a fidget toy or reaching ability like touching wall. All sessions will be individual. The initial training session will be undertaken in University of Plymouth. This will be followed by a recorded training video programme which can be accessible through Panopto- a University-led, web-based platform- undertaken in the participants' home for 30 minute sessions, three times a week over 6 weeks.
Study NCT05710588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor-cognitive dual-task training
Description: The intervention compromises (1) balance-related tasks which are selected among the tasks often used in balance rehabilitation and (2) cognitive secondary tasks might required to activate sensory and cognitive systems like listening podcast and memorizing the details about it or reading a tongue twister and repeating. intervention delivery will be the same with M-DTT group.
Study NCT05633186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moodbuster Life
Description: All participants get access to the Moodbuster Life intervention. Moodbuster Life is an online self-help intervention that contains 5 web-based modules focusing on lifestyle and coping: psycho-education, behavioral activation, physical activity, problem-solving, and worrying. All participants start with module 1, psycho-education. Next, participants can choose what module they wish to continue with. All modules take about 45 minutes to complete and contain text, exercises, video clips and preparing the home-work assignments. Executing the home-work assignments may take 20 minutes each week.
Study NCT05633186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: The participants randomized to receive this component will receive access to a mobile application. The aim of this app is two-folded, (1) used for diary ratings, (2) sending out personalized automated messages. First, the participants will rate their mood, sleep and related factors on a daily basis. The participants are prompted to rate the diary ratings three times a day (morning, afternoon, evening). Moreover, the application graphically pictures progression over time. Second, the application will send personalized automated messages. The content of the messages is informative, affirmative or encouraging. The investigators will use reinforcement learning (RL) to find so-called policies that show best long-term engagement and most sustained improvement of participants' mood. To drive choices, the investigators will use the data mentioned in the advising for the modules as well as behavioral data (mood ratings), data across all users is exploited.
Study NCT05633186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guidance by a coach
Description: A coach will provide support once per week at a scheduled time to participants who are allocated to receive support. The coaches are psychologists who are not part of the research team. The support will be provided via the Moodbuster Life messaging system and is focused on helping the participant work through the modules, showing empathy and motivating the participants to continue with the modules. The coaching is not aimed at developing a patient-therapist relationship.
Study NCT05633186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Content
Description: Participants who are randomized to this component, receive access to extra content that is based on the principles of motivational interviewing. This includes an extended first module that contains psychoeducation on the importance of motivations and on how persons can motivate themselves to engage with the interventions. Participants are asked about their life goals (long term) and intervention goals (short time) and are guided in how they should formulate these goals to increase the chance of success. Moreover, in each of the 4 modules a short exercise aimed at increasing motivation is included.
Study NCT05770622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First-dose trough dose adjustment calculator - using early TDM (first-dose trough) to determine an early dose adjustment if the predicted steady-state trough is outside of target range (10-20mg/L)
Description: CALCULATOR: A 'First-dose trough dose adjustment calculator' was developed based on a population pharmacokinetic model. A participant's post-menstrual age, weight, creatinine, target trough concentration, dose, dosing interval and first-dose trough concentration (taken immediately before the second dose is due) are entered into the calculator. The calculator determines if a dose adjustment is required (based on whether the predicted steady-state trough concentration is \<10mg/L or >20mg/L) and, if required, recommends a new adjusted dose.
Study NCT05068830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ExPlas
Description: ExPlas (plasma from fit donors) is a Investigational Medicinal Product. ExPlas is plasma drawn by plasmapheresis once a month for 4 months, from a total of 30 donors (aged 18-40, BMI ≤27 kg/m2 and VO2max >50 mL/kg/min) at the Blood Bank at St. Olavs Hospital. All unites will be virus inactivated by the Intercept method (Cerus corporation, US) in accordance with the procedures at Blood Bank at St. Olavs Hospital.~The transfusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline.
Study NCT05068830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octaplasma
Description: Octaplasma is defined as a Investigational Medicinal Product. Octaplasma is human pooled plasma produced by Octapharma (Lachen, Switzerland). The transfusion volume will be 200 mL at every time point .~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline.
Study NCT05068830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is provided by the hospital pharmacies in Central Norway. The infusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 saline infusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline.
Study NCT05261490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maplirpacept (PF-07901801)
Description: PF-07901801 Escalation (3-dose-level 12, 24, and 48 mg/kg), in combination with Pegylated Liposomal Doxorubicin (40mg/m2) will be administered by intravenous infusion.
Study NCT05261490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin (PLD)
Description: RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in combination with pegylated liposomal doxorubicin 40mg/m2
Study NCT04856865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose ADP101
Description: Active powder formulation
Study NCT04856865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose ADP101
Description: Active powder formulation.
Study NCT04856865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pooled Placebo
Description: Placebo powder
Study NCT05908656 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Investigational procedure
Description: Subjects that consent will have a single blood draw either via a finger stick or via venous blood draw (blood will be placed on a 5 spot blood card) used to determine whether they have Gaucher Disease or ASMD
Study NCT05084300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: A total of 10 PNE sessions (Neuroscience pain education) will be carried out, two each week in addition medical treatment similar to control group (Usual care). The NPE sessions will be conducted by an experienced NPE certified physical therapist in 35 minute face-to-face group sessions. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
Study NCT05084300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: The control group (Usual care) is treated with usual treatment, managment or medication for fibromyalgia, anxiolytics, antidepressants, analgesics. Depending on the medical needs and criteria of patients´s primary care physician.
Study NCT05084300 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The control group (Usual care) is treated with usual treatment, managment or medication for fibromyalgia, anxiolytics, antidepressants, analgesics. Depending on the medical needs and criteria of patients´s primary care physician.
Study NCT05547750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K2
Description: Vitamin K2 is a fat-soluble and one of the body's indispensable vitamins. It is mainly synthesized by gut bacteria in the body and plays a role in the mitochondrial electron transport chain. It boosts calcium metabolism, acts on osteoblasts, and promotes bone tissue calcification. It also inhibits osteoclasts from causing bone resorption, thus increasing bone density, and preventing osteoporosis. Furthermore, it regulates the use of calcium and promotes the inhibition of vascular calcification by matrix Gla protein (MGP) activity. Vitamin K2 supplementation at recommended dosage does not affect vitamin K-dependent coagulation factors' activity. It does not enhance the carboxylation of prothrombin in healthy individuals. Vitamin K2 administration does not alter the hemostatic balance in healthy populations without anticoagulation treatment. Thus, vitamin K2 is deemed to have a good safety profile.
Study NCT05547750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar-looking placebo tablets
Study NCT05608941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training
Description: The training program will be carried-out with the Orygen Dual Valve. Individuals will perform a home-based intervention, split into two daily 20-min sessions (morning and afternoon), totaling 40 min per day, seven times a week, during eight weeks. Each daily session will be composed into four blocks of three minutes, with a two-minute rest between blocks. The initial training load for each participant will be set at 60% of his/her maximal baseline MIP and MEP for both inspiratory and expiratory strength training, respectively. Borg score of dyspnea and effort was also considered for adjusting training intensity, and scores from 4 to 6 were targeted. Once a week, a trained researcher will visit their homes, the MIP and MEP will be evaluated and the training load will be progressed to ensure that 60% of the new pressure values are maintained.
Study NCT05608941 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring.
Study NCT05574075 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diffusion tensor imaging
Description: white matter imaging markers
Study NCT06138639 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SGT-003
Description: Adeno-associated virus serotype SLB101 containing the human microdystrophin gene (h-µD5)
Study NCT06273527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COGENT
Description: COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.
Study NCT06273527 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Program
Description: The Sham Program will be a similar task which researchers think will be less effective in training thinking skills.
Study NCT04648891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Subcutaneous injection 0.5cc 2% in 1:100,000 epinephrine
Study NCT04648891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating wand
Description: a vibrating instrument held adjacent to the cricothyroid space
Study NCT05215262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treat Act Know Engage (T.A.K.E.) Steps
Description: Intervention sessions will consist of psychoeducation, HIV/STI goal identification, referral to HIV testing and PrEP, and communication skill building.
Study NCT05215262 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard or Care
Description: S.O.C. arm will receive treatment as usual. After the baseline interview, participants will be referred to their PCP for management of any clinical issues that arise. Their clinic visit schedule will follow their clinical needs and recommendations of their clinic provider
Study NCT04861571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention with very low calorie diet (VLCD)
Description: The VLCD program will last 8 weeks. The only sources of nutrition during this phase are the Optifast® products providing up to 800 kcal per day. Two liters (67.63 fl oz) of water should also be consumed each day. Participants will be instructed to use 5 replacement meals per day (800 kcal total) with 40% of calories as protein, 40% as carbohydrate, and 20% as fat.
Study NCT04861571 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Arm
Description: The control group will consume a lower calorie diet and will be instructed to reduce their usual intake of normally consumed foods by up to 500 kcal per day but no less than 1200 kcal per day.
Study NCT05761444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atozet 10/40 mg or 10/80 mg
Description: Atozet 10/40 mg or 10/80 mg Dosage Formulation: Tablet Dosing Instructions: oral. Take 1 tablet daily
Study NCT05761444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipitor 40 mg or 80 mg
Description: Lipitor 40 mg or 80 mg Dosage Formulation: Tablet Dosing Instructions: oral. Take 1 tablet daily
Study NCT06463340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGR-3515
Description: SGR-3515 will be administered orally with an intermittent schedule.
Study NCT06466915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Group Dex received 1 mcg/kg of dexmedetomidine intra-nasal 10 minutes before the surgical procedure ended.
Study NCT06466915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Group Pofol received 1 mg/kg propofol IV before the extubation.
Study NCT04813146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLP
Description: Synchronization of dietary intake with circadian rhythm of the body
Study NCT04813146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLP along with Physiotherapy
Description: Synchronization of dietary intake along with Physiotherapy (aerobic, flexibility, resistance and balance exercises)
Study NCT04813146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy given only (aerobic, flexibility, resistance and balance exercises)
Study NCT04686305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd
Description: T-DXd: administered as an IV infusion
Study NCT04686305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab: administered as an IV infusion
Study NCT04686305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin: administered as an IV infusion
Study NCT04686305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin: administered as an IV infusion
Study NCT04686305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed: administered as an IV infusion (drug not used)
Study NCT04686305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: Volrustomig: administered as an IV infusion
Study NCT04686305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Rilvegostomig: administered as an IV infusion
Study NCT06512805 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine transport
Description: 1. Before the transfer of the patient:~   ① The doctor determines the destination of the patient based on the patient's condition and issues transfer orders.~  * The responsible nurse assesses the patient's consciousness, circulation, respiration, etc., and fills out the Transfer Patient Handover Record in the transferring department section.~     * The responsible nurse prepares the equipment, medications, and patient's belongings required for the transfer.~2. During the transfer:~   Monitor the patient's vital signs.~3. Upon arrival at the receiving department:~   * Place the patient with the receiving department nurse. ② Verbally hand over the patient's condition to the receiving department nurse and hand over the patient's belongings and medications.~     * The responsible nurse of the receiving department completes the remaining part of the Transfer Patient Handover Record.
Study NCT06512805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-guideline transfer
Description: In the intervention group, nurses receive implementation strategies developed during the preparation phase. These strategies aim to modify the behavior of healthcare personnel through implementation, thereby conducting evidence-based (based on the guidelines) in-hospital transfer interventions for pediatric patients.The interventions received by pediatric patients are derived from the recommended practices evaluated for evidence availability in the guidelines. These include specific transfer procedures, the Transfer Risk Level Classification Criteria, Personnel Qualifications, Equipment, and Medications Allocation Based on Transfer Risk Level, Transfer Preparation Checklist, and Transfer Handover Checklist 2.0.
Study NCT06418295 — intervention group
Intervention type: OTHER
Intervention: Unilateral thoracotomy
Description: Unilateral thoracotomy to proceed as per standard of care guidelines. Thoracic epidural analgesia, or patient controlled analgesia (PCA) pumps will be offered to each study participant as per standard of care. Pre- and post-operative (post-operative day 1 and 3 months) pain scores and blood samples will be collected. Blood samples will be analyzed to determine the concentration of cytokines, chemokines, and growth factors that are potentially associated with CPSP (epidermal growth factor, eotaxin, fibroblast growth factor basic, G-CSF, GM-CSF, human growth factor, IFN-α, IFN-γ, IL-1ra, IL-1β, IL-2, IL-2r, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40/p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MIG, MIP-1α, MIP-1β, RANTES, TNF-α, and VEGF). DNA promotor methylation for these targets will also be investigated.
Study NCT06176989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: 100mg PO (orally) once daily, on days 1-28 of a 28-day cycle